Collegium Pharmaceutical, Inc (COLL) Stock Price & Analysis

Collegium Pharmaceutical, Inc (COLL) fell 0.72% to USD 23.53 as of September 8, 2026 at 06:21 UTC, according to Nexqual real-time market data.

COLL last closed at USD 23.53; the session ranged USD 23.37–24.32 on volume of 901,142 shares. Market capitalization is —, with a 52-week range of USD 23.37–50.79 (NMS). Source: Nexqual, September 8, 2026 at 06:21 UTC.

Key Statistics (as of September 8, 2026 at 06:21 UTC)

Technical Analysis (COLL)

Nexqual's technical model rates COLL "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:21 UTC.

From Collegium Pharmaceutical, Inc's Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• In January 2026, a generic equivalent of Nucynta IR 50mg, 75mg and 100mg tablets was approved under an abbreviated New Drug Application ("ANDA") filed by a third party with the FDA, which carves out pediatric use from its label.
• Drug Substances The API used to formulate the products in our portfolio and DEA drug scheduling are as follows: Oxycodone, tapentadol, methylphenidate, and buprenorphine are classified as narcotic controlled substances under U.S. federal law.
• Paul, Minnesota where it is converted into individual dosage units and, ultimately, into finished goods. 6 Table of Contents Xtampza ER is manufactured using a proprietary process.
• In addition, we use a unique and proprietary process to manufacture our products that requires significant know-how, which we currently protect as trade secrets.

Partnerships

• We have entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. ("Hikma"), pursuant to which we granted Hikma rights relating to an authorized generic version of the Nucynta Products in the United States.
• We are party to a license agreement with Grünenthal Gmbh (the "Grünenthal License") pursuant to which we license the right to commercialize the Nucynta Products in the United States and its territories and a license agreement with Shionogi (the "Shionogi License") pursuant to which we license the right to commercialize Symproic in the United States and its territories.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:21 UTC. This page is informational and not investment advice.